We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Committee Wants Stronger Warning for Serevent
FDA Advisory Committee Wants Stronger Warning for Serevent
November 30, 2007
The FDA’s Pediatric Advisory Committee recommended that the agency strengthen the boxed warning for GlaxoSmithKline’s (GSK) asthma treatment Serevent to better reflect the risks of the product in children.